The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...
A review of postmarket safety studies by the US Food and Drug Administration (FDA) has found no significant increase in risk for serious asthma-related outcomes when a long-acting β-agonist (LABA) is ...
Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced the first patient has been dosed in its Phase 2b ...
When added to ICS, tiotropium and LABAs perform similarly for asthma patients. What is the effect of ICS/LABA controller therapy on asthma in patients with persistent cold airway hyperresponsiveness, ...
The FDA has removed a boxed warning on medicines delivering a combinations of inhaled corticosteroid (ICS) and long-acting beta agonists (LABA) drugs. The FDA has removed a boxed warning of asthma ...
The trials did show that ICS/LABA combination medicines were more effective in decreasing asthma attacks (e.g., the need to use oral corticosteroids) compared to ICS alone. This additional information ...
Photomicrograph of salivary gland of a person with Sjögren’s syndrome, characterized by the abnormal migration of of lymphocytes T and B. Here the lymphocytes T and B appear in mauve. Investigators ...
For patients with moderate to severe chronic obstructive pulmonary disease (COPD), treatment options include a long-acting beta-agonist (LABA) alone or a LABA combined with an inhaled corticosteroid ...
Inhaled corticosteroid–long-acting beta-agonist (ICS-LABA) inhalers are widely prescribed for asthma and chronic obstructive pulmonary disease. ICS-LABAs are largely interchangeable within the class; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results